The role of the RGDX putative receptor-recognition sites, which are present on the a chains of fibrin, in promoting platelet adhesion has been examined in flowing whole blood using the rectangular perfusion chamber at wall shear rates of 340 and 1,8oo/s. Platelets adhered to a comparable extent to surfaces coated with native fibrin and surfaces coated with fragment X-fibrin, a product of limited fibrinolysis that lacks the RGDS sites normally present at positions 572 to 575 of the a chains. The strengths of these adhesive interactions were comparable based on the concentrations of the antiadhesive peptide D-RGDW required to block platelet deposition to native and fragment X-fibrin at both low and high wall shear rate. Blocking either or both RGDX sequences with peptidespecific monoclonal antibodies did not inhibit platelet deposition in perfusion experiments per-DHESION OF CIRCULATING human blood platelets to the strands of a developing fibrin clot contributes to the formation of a life-threatening thrombus'*2 and presents a barrier to the rapid restoration of blood flow through an occluded artery during thrombolytic Understanding the molecular basis of platelet-fibrin adhesive interactions can contribute to improved thrombolysis, but advances in the clinic have often outpaced developments in the laboratory. For example, reagents displaying an RGD-integrin targeting motif are under active investigation as antithrombotic drugs:' yet the role of fibrinogen's RGD sequences in promoting interactions with platelets remains controversial.
DHESION OF CIRCULATING human blood platelets
to the strands of a developing fibrin clot contributes to the formation of a life-threatening thrombus'*2 and presents a barrier to the rapid restoration of blood flow through an occluded artery during thrombolytic Understanding the molecular basis of platelet-fibrin adhesive interactions can contribute to improved thrombolysis, but advances in the clinic have often outpaced developments in the laboratory. For example, reagents displaying an RGD-integrin targeting motif are under active investigation as antithrombotic drugs:' yet the role of fibrinogen's RGD sequences in promoting interactions with platelets remains controversial.
Fibrinogen is known to bind tightly to aI& integrin receptors present in a functional conformation on the surface of stimulated platelet^.^^ The dimeric 340-kD fibrinogen molecule has three pairs of potential receptor-recognition sites: RGDF sequences at positions 95-97 of the Aa chains, RGDS sequences at positions Aa 572-575, and HHLGGAK-QAGDV sequences at positions 400-411 of the y chains.'" The observation that synthetic peptides spanning these sequences can block essentially all platelet-fibrinogen adhesive interaction^""^ has led to a multisite binding model in which all three types of sites participate in ligand binding."
Conversely, recombinant fibrinogen molecules lacking either RGDX sequence function normally, whereas engineered fibrinogen variants lacking the native y chain sequence interact only weakly with platelets.'"~'' This information, coupled with electron microscopic observations that show the a,& integrin exclusively bound to the distal D domains of the multinodular fibrinogen molecule,I6 strongly suggests that the RGD sites are not necessary for fibrinogen to serve as a molecular bridge during primary hemostasis.
Fibrin, the three-dimensional network that rapidly assembles after limited proteolytic cleavage of fibrinogen by thrombin, stabilizes the initial platelet-rich hemostatic plug (or nascent thrombus) and forms a tight seal until it is systematically disassembled by the fibrinolytic system. Fibrin binds to platelets more avidly than fibrinogen, probably through multivalent interactions with amps integrin~.'~"~ Unlike fibrinogen, fibrin polymers bind to platelets in a multiplicity of orientations, suggesting the involvement of more than one type of molecular recognition code?" Since the y chain sites on fibrin may be inaccessible to other macromolecules due to their proximity to regions involved in polymerization?l the possibility remains that fibrin uses either or both of its a-chain RGD sequences in binding to platelet integrin receptors. Further, the conformation of the carboxyterminal regions of the fibrin a-chains changes during polymerization in a manner that could make the RGDS sites available for intermolecular interaction^.^^.^^ Electron microscopic images of fibrinogen and desA-fibrin have shown the carboxy-terminal regions of both a chains reside in close proximity to the central domain of the molecule. In contrast, the a chains on desAB-fibrin dissociate from the central region and desAB-fibrin polymers were sometimes observed to interact via their a chain carboxy-terminal regions.22323 These observations suggest the possibility that the RGDS sites could become available for additional intermolecular interactions as fibrin polymerizes.
This study was initiated to determine the role of the fibrin RGDX sites in supporting platelet adhesion in flowing blood. These studies use the rectangular perfusion an experimental system that we have utilized to study platelet Elution Volume (ml) adhesion to fibrinz5 under shear conditions representative of those in a freely flowing artery (wall shear rates in the range of 1 0 0 to 600/s) as well as in a partly occluded blood vessel
We have previously shown that platelets readily and avidly adhere to fibrin-coated surfaces in a process that is critically dependent on the all& integrin,'y.26 with additional shear-rate-dependent stabilization provided by von Willebrand factor/glycoprotein Ib interactions.2h Although we have already shown that synthetic RGD peptides are effective inhibitors of platelet adhesion," evidence will be presented here to show that the RGDX sequences on the fibrin LY chains are not required for normal platelet-fibrin adhesive interactions in flowing blood. Resolution of this paradox will be discussed.
MATERIALS AND METHODS
Purification and characterization of Jihrinogen. Human fibrinogen (98% clottable protein, plasminogen-free; American Diagnostics, Greenwich, CT) was further purified by size exclusion chromatography on Sepharose 4B in 0.05 moVL ammonium acetate, pH 7.4 containing 0.01 mglmL bovine pancreatic trypsin inhibitor (Aprotinin from Sigma Chemical CO, St Louis, MO). Peak fractions ( Fig  I ) were pooled, lyophilized, stored in aliquots at -70°C for up to 3 months, then reconstituted in distilled water before coating coverslips. The protein concentration was determined by absorbance measurements using an extinction coefficient at 280 nm of I .6 mL/ mg cm, as previously described."
Preparation and characterization of fragment X. Fragment X, a fibrinogen proteolysis product with truncated Aa chains, was produced by limited plasmin digestion of fibrinogen in a pH 7.4 buffer containing 0.3 mol/L NaCI, 0.01 moVL HEPES, and 0.02 molL CaClz at 23°C. As illustrated in Fig 2, conditions were optimized in a pilot digestion mixture containing 50 pmol/L fibrinogen and 0.015 UlmL plasmin. The time course of fibrinogen degradation was monitored by laser light scattering intensity measurements that provide a direct index of molecular weight." The right-angle scattering intensity decreased upon addition of plasmin and approached a plateau with a half-time of =20 minutes.
Samples were also removed at selected times, reduced, and unfolded with excess dithiothreitol ( D m ) and sodium dodecyl sulfate (SDS), then analyzed by polyacrylamide gel electrophoresis (PAGE) monitored by absorbance at 280 nm using a Uvicord S recording spectrometer (LKB Instruments, Incl.
The bars beneath each peak depict fractions of fibrinogen or fragment X pooled for further studies.
(Insert) SDS-PAGE of disulfide-bond reduced samples of the fibrinogen (7 p g ) and fragment X 110 p g l pools stained with Coomassie Brilliant Blue.
on 10% gels." After staining with Coomassie Brilliant Blue, the gels were analyzed by laser scanning densitometry (Zeineh Model SL-TRFF, Biomedical Instruments, Inc. Fullerton, CA) to obtain the integrated intensities of peaks corresponding to the Aa, BP, and y chains of fibrinogen (Fig I , insert) . Time-dependent fractional changes in the intensity of each band are depicted in Fig 2. A digestion time of 45 minutes was selected for preparative work, based on the following considerations: (1) the scattering intensity had decreased by =30% at this time, consistent with removal of the 2-X 40-kD carboxy-terminal regions of the fibrinogen a chains"'.''; (2) the Aa-chain staining intensity was reduced more than threefold; and (3) BP-chain degradation, indicative of additional proteolysis," became significant at later times.
Fibrinogen (4 mL at 20 mglmL) was digested with plasmin (0.015 U/mL) for 45 minutes at room temperature; proteolysis was stopped by addition of excess bovine pancreatic trypsin inhibitor. The mixture was applied to a 1.5-X 80-cm column of Sepharose 4B equili- (Fig 1) were pooled, lyophilized, and stored in aliquots at -70°C. SDS-PAGE of disulfide-bond-reduced samples (Fig 1, insert) followed by scanning densitometry showed a substantial reduction (>85%) in the staining intensity of the Aa chain band, minimal changes in the BP and y bands, and the appearance of new bands with molecular masses of = 15 and 22 k D , consistent with the subunit composition of fragment X." Fragment X concentrations were determined by absorbance measurements using an extinction coefficient at 280 nm of 1.42 mL/ mg cm.30 Absorbance measurementsz7 showed that fragment X exhibited a clottability of 82%, consistent with literature reports.3o Laser light scattering kinetic measurements" showed fragment X clotted at a rate comparable to native fibrinogen and formed thick fibers (massfiength 430% of native fibrin).
Preparation of coverslips coated withfibrin and fragment X-jbrin. Eighteen-millimeter-square glass coverslips were cleaned in ethano1:HCI (l:l, by volume), rinsed in distilled water, and dried in air before spray-coating with fibrinogen (or fragment X) + thrombin (0.4 NIH U/mL; Sigma) in the volatile ammonium acetate buffer to achieve a fibrin density of either 20 or 50 pgkoverslip, as previously described.19,26 Practical considerations necessitated drying the coverslips before use; each day's perfusion experiments required 60 to 100 fibrin or fragment X-fibrin-coated coverslips. To insure a uniform set of coated coverslips, these time-consuming coating procedures were performed the day before each perfusion series. We have previously shown that similar adhesion profiles resulted from fibrincoated coverslips and those subsequently blocked with albumin solution and then kept in phosphate-buffered saline until their use in perfusion experiments." Additional experiments examined fibrincoated coverslips that were not dried before perfusions. No differences were found in the number of adherent platelets, and no differences in platelet morphology were observed."
Time-dependent turbidity measurements confirmed our previous observations (by laser light scattering kinetics and epifluorescence microscopy26) that under the buffer conditions used for preparation of fibrin-coated coverslips, the formation of thick fibrin fibers took place over a period of 10 to 30 minutes. As the coverslips were allowed to dry for at least 2 hours before perfusions, these results indicate that virtually all fibrinogen (or fragment X) was converted to fibrin (or fragment X-fibrin) on coverslips under these conditions. Furthermore, measurements of the time course of fibrin assembly by quantitative fluorescence microscopy in a system with similar geometry, ie, in volumes <0.1 mL on glass slides, yielded kinetics that paralleled those measured in bulk by light ~cattering.'~.~' Control coverslips were coated with 100 pL of ammonium acetate buffer, or buffer containing 0.4 NIH U/mL thrombin. We have previously shown that blocking fibrin-coated coverslips with the irreversible thrombin inhibitor PPACK (10 pmoVL, a 2,000-fold molar excess over the thrombin concentration used for polymerization) had no effect on platelet adhesi~n.'~.~~.'' We also showed that coverslips coated with buffer containing 0.4 NIH U/mL thrombin (but no fibrin or fibrinogen) did not support adhesion during 5-minute whole blood perfusion experiments."
Limited plasmin digestion of fibrin-coated coverslips. Selected experiments involved fibrin-coated coverslips that were exposed to an active fibrinolytic system to induce partial fibrin degradation. Coverslips coated with fibrin (50 pglcoverslip) were exposed to plasminogen (60 nmom) and recombinant tissue-type plasminogen activator (rt-PA) (0.4 nrnom; Genentech, Inc, San Francisco, CA) for up to 90 minutes at room temperature. Digestion was stopped by washing the coverslips with phosphate-buffered saline containing aprotinin. These coverslips were used for perfusions, as described earlier. The fibrin on selected coverslips was dissolved in 2% SDSl 2% DTT by incubation and frequent agitation during a 90-minute period at 60°C. The solubilized fibrin was analyzed by SDS-PAGE using a Phannacia Phast System (Phannacia, Uppsala, Sweden) with silver staining detection. The intensities of the stained bands were determined by laser scanning densitometry.
Preparation and characterization of synthetic peptides.
were synthesized by the Protein Analysis Core Laboratory of the Cancer Center of Wake Forest University (Winston-Salem, NC), using an automated peptide synthesizer (model 430A; Applied Biosystems, Inc, Foster City, CA) using protocols previously described." Each peptide was characterized by high-performance liquid chromatography using an Aquapore C-l8 (Applied Biosystems) reverse-phase column with 0.1% trifluoroacetic acid as the mobile phase and CH3CN containing 0.08% trifluoroacetic acid as the mobile-phase modifier.
Each peptide was shown to have the expected amino acid composition and the correct sequence determined by sequence analysis using an Applied Biosystems 475 automated peptide sequencer. Aliquots of each peptide were dissolved in 0.1 molL acetic acid and dried under vacuum; the mass of peptide in representative aliquots was determined by quantitative amino acid composition analyses. Results from our laboratories have previously shown that D-RGDW inhibited platelet aggregation with ICso values less than 2 pmoV L,'9.3s whereas WDGR had no effect on platelet aggregation at concentrations up to 300 p m~l / L .~~ Isolation and characterization of RGDX-spec@ monoclonal antibodies (MoAbs). Two MoAbs, each specific for one of the two RGDX sequences present on the Aa chains of human fibrinogen, were generously provided by Z . Ruggeri (The Scripps Research Institute, La Jolla, CA)? in the form of ascites fluids. MoAb 134B-29 was raised against a synthetic peptide (SSTSYNRGDSTFESK) corresponding to residues 566-580 of the fibrin or fibrinogen (Y chain; MoAb 155B-16 was raised against a synthetic peptide (TTNI-MEILRGDFSS) corresponding to a-chain residues 87-100.33
IgG and Fab isolations. Purified IgG was isolated from each ascites fluid by adsorption to a 7-mL column of Protein G-Sepharose (Pharmacia-LKB, Piscataway, NJ) in phosphate-buffered saline (PBS). After extensive washing, bound material was eluted with 0.1 mol/L glycine, pH 2.7; each fraction was adjusted to neutral pH before exhaustive dialysis versus PBS at 4°C. Fab fragments were prepared from each purified IgG by limited digestion with immobilized papain (6 hours at 37"C), followed by isolation on Protein Aagarose using a Pierce ImmunoPure Fab Preparation Kit (Pierce Chemical CO, Oud-Beijerland, The Netherlands). MoAb and Fab concentrations were determined by absorbance measurements using an extinction coefficient at 280 nm of 1.4 mL/mgl~m.~' SDS-PAGE (Pharmacia Phast System) confirmed the purity of the resultant IgG and Fab samples.
Enzyme-linked immunosorbent assay (ELISA) protocols. An ELISA was used to measure the affinity of each IgG or Fab sample for fibrinogen and fragment X. All incubations were performed for 1 to 2 hours at 37°C and were followed by extensive washes. Fibrinogen (or fragment X) at a concentration of 7 to 8 nmol/L in 0.05 m o m NaHCO,, pH 9.6 was incubated in the wells of plastic microtiter plates, then each well was blocked with Michaelis buffer containing 0.75% bovine serum albumin and 0.025% Tween. Primary antibodies, ie, anti-RGDX IgG or Fab, were added at concentrations ranging from 0.1 nmol/L to 100 nmol/L. Detection involved a secondary rabbit-antimouse antibody conjugated to horseradish peroxidase; orthophenylenediamine was used as substrate with absorbance measurements at 490 nm in a Vmax Microtiter Plate Reader (Molecular Devices, Palo Alto, CA).
The resultant absorbance versus (MoAb) curves were fit to a saturable binding model3* using a nonlinear regression routine (Sig-maPlot; Jandel Scientific CO, San Rafael, CA) to determine the dissociation constant (Kd) for each antibodydigand combination. These analyses confirmed the specificity of MoAb 155B-16 for the RGDF sequence, in that this MoAb bound tightly to both fibrinogen and fragment X (Kd, 0.3 nmol/L). Fab fragments obtained from MoAb 155B-16 exhibited a much lower affinity for both ligands, with Kd values ranging from 60 to 70 nmollL.
Although MoAb 134B-29 did discriminate between fragment X (which lacks the RGDS sequence) and fibrinogen, the differences in affinity were relatively modest. MoAb 134B-29 bound to fibrinogen with a Kd of 8 n m o m and to fragment X with a Kd of =50 nmoVL. The fact that the preparation of fragment X that was used contained up to 15% intact Aa chains may account for part of the immunoreactivity of MoAb 134B-29 for fragment X in this ELISA. Fab fragments obtained from MoAb 134B-29 bound rather weakly to both fibrinogen and fragment X, with dissociation constants ranging from 1 to 3 pmol/L.
Perfusion procedures. Perfusions were performed in a parallel plate perfusion chamber, the characteristics of which have been previously de~cribed.'~ Whole blood obtained by venipuncture from healthy, volunteer donors was anticoagulated with one-tenth volume 110 mmol/L trisodium citrate. Perfusates were recirculated through the perfusion chamber for either 3 or 5 minutes at wall shear rates of either 340 or 1,600/s. Each perfusion involved a separate 15-mL aliquot of whole blood that was recirculated through the perfusion chamber for either 3 or 5 minutes at wall shear rates of either 340 or 1,600/s. During perfusions at 340/s, the blood passes through the chamber five times in 3 minutes and nine times in 5 minutes; at I ,600/s the number of passages are 11 and 18, respectively.
Our earlier work has shown that platelet adhesion to fibrin is independent of platelet count over the range 1 to 3 X 10' platelets/ m L Z 6 ; all experiments performed in this study used blood with platelet counts in this range. We have also previously shown by determination of the platelet count before and after perfusions with singleparticle counting that minimal platelet loss (ie, less than 30%) occurs during 5-minute recirculating perfusion experiment^.'^ Note that maximal adhesion at 1,600/s is reached with a platelet number of about 108/mL; thus, even considering the effects of single-platelet loss, the platelet count is still sufficient for maximal adhesion.33 At the end of the 3-or 5-minute perfusion period, the chamber was washed for 30 seconds, at the same flow rate as the perfusion, with HEPES-buffered saline to remove any loosely bound red blood cell^.'^^'^ Platelet losses are usually less than 5% during this washing procedure.
After perfusions, the coverslips were removed, rinsed with 10 mmoVL HEPES, 150 mmol/L NaCI, pH 7.4, fixed in 1% glutaraldehyde, dehydrated in methanol, and stained with May-GriinwaldGiemsa.26 The extent of surface coverage by adherent platelets was evaluated by light microscopy of stained coverslips at magnification X 1,000, aided by an image analyzer (Quantimet 720; Imago, Royston, UK). A minimum of 30 randomly selected areas of each coverslip was evaluated, and the results from duplicate coverslips averaged. Statistical significance of the difference between means was determined with the paired t-test. 39 The within-experiment variation was determined by performing a control perfusion at the beginning and end of each perfusion series. This procedure was repeated for each condition of time and wall shear rate. The percentage of surface covered in these duplicate perfusions, performed with blood with a single donor, agreed to within 5% to 10%. The mean of these two control perfusions is defined as relative adhesion = 1.00, and the range in this parameter is cited in the figures presented here.
The results of perfusions in the presence of an effector are expressed as relative adhesion, ie, a fraction of the control adhesion. These effector perfusions were repeated twice, each time with a separate donor. The mean and range of the resultant relative adhesion parameters in the presence of an effector are cited in the figures that follow. This analysis procedure was chosen to minimize donor-todonor variations. When required, synthetic peptides were dissolved in PBS and added to the perfusates, which were then prewmed to 37°C for 5 minutes before the start of the perfusion. The concentration of peptide in the plasma was calculated based on a 40% hematocrit. Our earlier work also showed that the concentration of an inhibitory peptide such as D-RGDW required to achieve 50% inhibition (ie, the ICso value) provides a convenient index of the strength of platelet-fibrin or platelet-fibrinogen adhesive interactions under flow cond i t i o n~.~~ Here we extend that analysis to fragment X-fibrin using a competitive inhibition model that relates the fraction of control adhesion, F(p) to the [D-RGDW]I9:
Selected experiments involved preincubation of fibrin-coated coverslips (or those coated with fragment X-fibrin) with RGDX-specific MoAbs before perfusions. To block all potential adhesive sites on the coated Coverslips, each coverslip was incubated for at least 2 hours with a 2-to 10-fold molar excess of antibody over RGDX sites. These coverslips were washed briefly with PBS before their use in perfusions.
Perfusions with blood from an ajibrinogenemic patient. A limited number of perfusion experiments were also performed with blood obtained from a patient (under the care of the Department of Hematology at University Hospital Utrecht) whose plasma contained undetectable levels of fibrinogen (<l0 pg/mL by ELISA). This patient had a normal platelet count (240,000 pL), but no fibrinogen could be detected within their platelets. Levels of clotting factors assayed were within the normal range for this patient, as indicated by the following parameters: factor 11, 11 1%; factor V, 135%; factor VII, 97%; factor X, 123%; and antithrombin IIl, 101%. This individual had a normal plasma von Willebrand factor concentration of 11.1 pg/mL.
RESULTS
Platelet adhesion to fibrin and fragment X-jibrin. Results obtained in a series of whole blood perfusion experiments showed that platelets adhered to the same extent to surfaces coated with either native fibrin or fibrin prepared from fragment X (fragment X-fibrin) ( Table 1 ). The fragment X preparation used for these studies was produced by limited plasmin digestion of fibrinogen, followed by size-exclusion chromatography to obtain an 82% clottable derivative that contained less than 15% intact a chains. Laser light scattering showed this fragment X-fibrin was comprised of fibers with a massflength that is 80% that of native fibrin (Fig 1  and Materials and Methods).
Whole blood perfusion experiments showed that 22% ? 8% surface coverage by adherent platelets resulted in 5 minutes at a wall shear rate of 340/s when coverslips were coated with fibrin, compared with 31% -t 6% surface coverage with fragment X-fibrin (n = 2, P < .l). Likewise, at the higher wall shear rate of 1,600/s, 44% ? 19% of the fibrin surfaces were covered with platelets, compared with 44% ? 37% coverage with fragment X-fibrin (n = 2, P > .25). As illustrated in Table 1 , a similar pattern of comparable platelet adhesion to intact and partly degraded fibrin resulted when coverslips were coated at a lower density (20 pg proteid coverslip) and perfusions performed for a shorter time (3 minutes).
These results provide a strong indication that an intact RGDS receptor-recognition motif is required to support platelet adhesion to fibrin in flowing blood. We note that this sequence is present twice on native fibrin, at positions 572-575 of the a chains," but has been removed from fragment X by limited plasmin dige~tion.~'
Inhibition of platelet adhesion to jibrin and fragment Xjibrin by D-RGDW. We have previously shown that the synthetic peptide D-RGDW is an effective inhibitor of platelet adhesion to fibrinogen and fibrir~.'~.~* Figure 3 depicts dose-response curves for D-RGDW inhibition of platelet adhesion to native and fragment X-fibrin at two wall shear rates, 340 and 1,600/s. The solid lines resulted from fitting the data to a competitive inhibition model (as described in Materials and Methods). This analysis yielded comparable ICso values for both surfaces. For example, at 3401s adhesion to native fibrin was inhibited by 50% at a peptide concentration of 30 2 17 pmol/L, whereas 17 t 7 pmoVL D-RGDW yielded this level of inhibition with fragment X-fibrin. Consistent with our earlier observation^,'^ D-RGDW was a more effective inhibitor at a higher wall shear rate. In the present study, ICso values of 3.4 2 1.7 pmol/L and 4.6 f 1.4 pmoV L resulted at 1,6001s with intact fibrin and fragment X-fibrin, respectively. Adhesion was reduced to nonspecific levels, ie, less than 5% of control values," at peptide concentrations above 30 pmol/L.
The control peptide WDGR differed from the active antithrombotic peptide D-RGDW, in that, at 340/s, it caused moderately increased adhesion to both fibrin and fragment X-fibrin, when present at 80 pmol/L. The reason for this effect is unclear. At 1,600/s, WDGR had no significant effect on platelet adhesion to either surface at concentrations up to 40 pmol/L.
In summary, these data provide additional support for the postulate that the RGDS sequences are not required for normal platelet adhesion to a fibrin-coated surface. The affinity of platelets for both intact and fragment X-fibrin was found to be similar, in that comparable concentrations of the potent antithrombotic peptide D-RGDW were required to block platelet adhesion to either surface in flowing whole blood.
Effect of anti-RGDX MoAbs on platelet adhesion tojibrin. The a chains of fibrin contain two types of RGD sequences that may contribute to platelet adhesion: RGDS sites (a 572-575) and RGDF sites (a 95-97). The contributions of these potential receptor-recognition sites to platelet adhesion in flowing blood were examined by blocking either or both RGD sites with peptide-specific M o A~s~~ (generously provided by Dr Z . Ruggeri). MoAb 134B-29 was raised against a synthetic 15-residue peptide that spans the a-chain RGDS sequence; MoAb 155B-16 was raised against a 14-residue synthetic peptide that encompasses the a-chain RGDF seq~e n c e .~~
The ability of each antibody to bind to immobilized fibrinogen was confirmed by ELISA in the present study (Materials and Methods).
Effects of anti-RGDS and anti-RGDF IgG on platelet adhesion. Fibrin-coated coverslips were incubated with an excess of RGD-specific MoAbs before exposure of these blocked coverslips to flowing whole blood in the rectangular perfusion chamber at 340 or 1,600/s. Results obtained at 340/s (Fig 4) show that neither anti-RGDX antibody alone produced a significant reduction in platelet adhesion to fibrin at this low wall shear rate. Exposure of fibrin-coated coverslips to a comparable concentration of an unrelated, control IgG also had no effect (fraction of control adhesion, 0.97). However, a modest (but statistically significant) reduction in adhesion was observed when fibrin-coated coverslips were preincubated with saturating concentrations of both anti-RGDX antibodies (fraction of control adhesion, 0.77 L 0.02, P < .025; range, .75 to .78 in duplicate experiments with separate donors). In summary, the minimal level of inhibition observed with anti-RGDX MoAbs under low shear conditions provides ad- ditional support for the hypothesis that the a-chain RGDS sequence is not essential for platelet adhesion to fibrin. These antibody inhibition experiments raise the distinct possibility that the a-chain RGDF sequence is also not required to support platelet adhesion to fibrin at low wall shear rates.
Additional experiments performed at the higher shear rate of 1,6OO/s yielded ambiguous results, because the extent of surface coverage increased some 50% to 70% in the presence of either or both anti-RGDX antibodies. Examination by light microscopy showed extensive platelet aggregation had taken place on coverslips preincubated with anti-RGDX antibodies. This phenomenon has also been observed by other investigators who have studied platelet adhesion to fibrin or fibrinogen under flow conditions in the presence of these reagents (Z Ruggeri, personal communication, February 1994). Because these anti-RGDX antibodies are divalent, there is a possibility that one antigen recognition site on an IgG molecule could bind to immobilized fibrin leaving the other site available to bind to plasma fibrinogen through one of its RGDX sites. This captured fibrinogen could promote platelet adhesion through its other RGDX sites, thus negating the potential inhibitory effects of these peptide-specific reagents. The experiments that follow were performed to address this possibility.
Effects of anti-RGDF Fab fragments on platelet adhesion.
As antibody-induced platelet aggregation may be due to either divalent antigen:antibody interactions or to the Fc portion of the IgG m01ecule~"~~' we also prepared Fab fragments of MoAb 155B-16 and MoAb 134B-29. ELISA determinations showed Fab 155B-16 bound with a dissociation constant of =70 nmol/L. Calculations based on this parameter indicate greater than 98% saturation of the fibrin-coated surface was achieved when the coverslips were preincubated with excess Fab 155B-16. Unfortunately, the much lower affinity of the Fab fragment of MoAb 134B-29 for fibrin HANTGAN ET AL (Kd, = l to 3 pmol/L) made it unsuitable for these studies. We estimated that only 4 0 % saturation could be achieved with the Fab fragment of MoAb 134B-29.
Perfusion experiments using Fab l55B-16 yielded relative adhesion values of 1 .OO t-0.04 and 0.76 t-0.12 at 340k and 1,6OO/s, respectively. Neither of these values were significantly different from control parameters ( P > . l ) . The lack of inhibition by RGDF-targeted Fab fragments lends additional support to the argument that platelet adhesion to fibrin in flowing blood is not critically dependent on the achain RGDF sites at either low or high wall shear rates.
Effect of anti-RGDX MoAbs on platelet adhesion tojbrin in the absence of plasma jbrinogen. Plasma fibrinogen introduces additional complexity into platelet adhesion studies, as competition for occupancy of the a,& integrin by soluble versus immobilized adhesive ligands can limit the extent of platelet adhesion to fibrin.33 Rapid adsorption of plasma fibrinogen onto antibody-blocked, fibrin-coated coverslips4' could also limit the effectiveness of anti-RGDX antibodies. Therefore, additional experiments were performed with blood obtained from an afibrinogenemic patient whose plasma contained an undetectable level of fibrinogen (ie, < IO pg/mL). This patient exhibited a normal platelet count (240,00O/pL), but no fibrinogen could be detected in their platelets. The levels of factors 11, V, VII, X, von Willebrand factor, and ATIII were all within the normal range for this patient. Perfusion experiments yielded a high level of platelet adhesion to fibrin, with 77.5% t-2.6% surface coverage in (duplicate) 3-minute perfusion experiments performed at 340k using a coating density of 20 pg fibrinkoverslip ( Fig  5) . Preincubation of the fibrin-coated coverslips with IgG 334B-29 (anti-RGDS MoAb) reduced adhesion by 26%, whereas IgG 155B-16 (anti-RGDF MoAb) reduced adhesion by 43%. Preincubation with both IgG reagents reduced adhesion by 54%, suggesting that the inhibitory effects of each IgG are additive (Fig 5) .
These observations suggest that the presence of plasma fibrinogen does limit the effectiveness of the anti-RGDX MoAbs as potential inhibitors of platelet adhesion. Conversely, the observation of a maximum twofold reduction in adhesion suggests that neither RGDX sequence is required for platelets to adhere to fibrin in flowing blood, at least at relatively low wall shear rates.
Effects of limitedjbrinolysis on platelet adhesion tojbrin. Proteolytic cleavage of the carboxy-terminal polar extension of the fibrin a chains is an early event in fibrinolysis, and one that removes the potential RGDS receptor-recognition sites from the fibrin clot.3' If these RGDS sites play a key role in supporting platelet adhesion, limited plasmin digestion of a fibrin-coated surface should result in decreased platelet adhesiveness to the residual, partly degraded fibrin. This concept was tested by exposing fibrin-coated coverslips to plasminogenh-PA before their use in whole blood perfusion experiments. The extent of fibrinolysis was quantified by SDS-PAGE of disulfide-bond-reduced, solubilized fibrin samples.
As illustrated in Fig 6 , exposure of fibrin surfaces to ongoing fibrinolysis did result in a time-dependent decrease in platelet adhesion. In fact, platelet surface coverage was reduced by greater than 90% after a 90-minute exposure to plasminogen (60 nmoVL) and rt-PA (0.4 nmoVL). SDS-PAGE showed that no significant reduction in the total quantity of fibrin remaining on (parallel) coverslips had occurred during fibrinolysis. Furthermore, the decrease in platelet adhesion was not strongly correlated with degradation of the fibrin a chains, as monitored by SDS-PAGE. In fact, the a chains staining intensity was reduced by only 12% after a 90-minute digestion period. These observations lend additional support to the hypothesis that the RGDS sequences are not critical for platelet adhesion to fibrin. However, an -20% reduction in y-chain staining was found after 90 minutes of digestion. This raises the possibility that degradation near the adhesive sites present in the carboxy-terminal region of the fibrin y chains" could be responsible for the major reduction in platelet adhesiveness found at this time.
DISCUSSION
This study has presented several independent lines of evidence showing platelet adhesion to fibrin in flowing blood does not require intact RGD sequences. Platelet-fibrin adhesive interactions were investigated in whole blood using the rectangular perfusion chamber at wall shear rates typical of those in either a free flowing or partly occluded artery. First, consider the putative integrin-targeting sequences present on the carboxy-terminal extension of each fibrin a-chain." We have shown that platelets readily adhered to surfaces coated with either native fibrin or fragment X-fibrin. Because the RGDS sites present at positions 572-575 of the fibrin a chains were removed from fragment X by limited plasmin dige~tion,~' this result clearly indicates the RGDS sequences are not required for normal platelet adhesion to fibrin under flow conditions. Furthermore, the affinity of platelets for fibrin appears unaffected by removal of the RGDS sites.
Competitive inhibition experiments with the potent antiadhesive peptide D-RGDW yielded comparable dose-response curves and similar IC5o values for both intact fibrin and fragment X-fibrin. Finally, we showed that blocking the RGDS sites on fibrin with a peptide-specific IgG whose epitope spans the fibrin a chain RGDS sites36 did not cause a significant reduction in platelet adhesion under low shear conditions. These experiments provide a strong indication that the fibrin RGDS sequences, present near the carboxyterminal extension of each fibrin a chain, do not play a major role in promoting platelet-fibrin adhesion in flowing blood.
A different strategy was used to probe the role of the RGDF sites present on the a chains at positions 95-97, midway through the coiled-coil regions of the multinodular fibrin m0lecule.4~ Studies were performed with a tight-binding peptide-specific antibody whose epitope includes the RGDF sequences on the fibrin a chains.36 Blocking fibrin-coated surfaces with saturating concentrations of this RGDF-specific MoAb (with either intact IgG molecules or Fab fragments) did not cause a significant reduction in platelet adhesion to fibrin in flowing blood under low shear conditions (340/s). Likewise, no significant inhibition was observed with anti-RGDF Fab fragments at a wall shear rate of 1,6OO/s (intact anti-RGDF IgG molecules caused platelet aggregation on fibrin-coated surfaces at this increased shear rate). In summary, blocking the fibrin a-chain RGDF sites did not result in decreased platelet deposition in whole blood. Therefore, we conclude that these potential receptor-recognition sequences are not critical for normal platelet adhesion to fibrin under flow conditions. Plasma fibrinogen introduces an additional level of complexity into any study of platelet-fibrin interactions performed in whole blood. The high concentration of this soluble adhesive protein may enable it to block potential a,& integrin sites on the platelet surface that would otherwise be available for interactions with surface-bound fibrin.33 Alternatively, rapid adsorption of fibrinogen onto fibrin surfaces42 initially blocked with anti-RGDX antibodies could negate some of the effects of this blocking strategy. Therefore, per-fusion experiments were performed with blood from an afibrinogenemic patient. High levels of platelet adhesion to fibrin resulted at 340ls, and this adhesion was moderately sensitive to inhibition by either anti-RGDX IgG. In fact, the combination of IgGs reduced adhesion by 54% with patient blood, whereas in normal blood the combined IgGs caused only 23% inhibition. These observations with afibrinogenemic blood raise the distinct possibility that the RGDS, RGDF, or both sites on fibrin may contribute to platelet adhesion. However, the fact that substantial platelet adhesion resulted when virtually all potential RGD-integrin targeting sites on fibrin were blocked supports the hypothesis that RGDX sequences are not required for platelet-fibrin adhesive functions.
Now consider the paradox that RGDX peptides are effective inhibitors of platelet-fibrin adhesive interactions, yet fibrin RGDX sites are not necessary to support these functions. We conclude that occupancy of ligand recognition sites on the a& complex by RGDX peptides prevents macromolecular adhesive ligands, especially fibrin, from gaining access to these regions of the receptor.
These findings extend to the physiologically relevant realm of clotted fibrin and flowing blood the results of other investigators who have shown that the RGDX sites are not required for fibrinogen to serve as a molecular bridge required for platelet a g g r e g a t i~n , '~~'~.~,~~ or for platelets to adhere to immobilized fibrinogen under static conditions.33,46-48 However, it must be emphasized that this subject has been controversial for more than a decade, as other investigators have concluded that truncated fibrinogen derivatives lacking RGDS sites are deficient in their ability to support platelet adhesive function^.^^-^'
What are the implications of the current study for understanding the complex processes of thrombus growth and thrombolysis? First, because cleavage can readily occur at several plasmin-sensitive regions of the fibrin or fibrinogen ~r-chains,~' clots formed in vivo are likely to be assembled from a mixture of intact and partly degraded fibrin molec u l e~.~~ Although the carboxy-terminal extensions of the a chains do contribute to the s t r~c t u r e~~.~~ and mechanical stability of the resultant fibrin we may conclude that fibrin devoid of its RGDS sites still presents a highly adhesive surface capable of promoting thrombus growth in rapidly flowing blood. Generation of plasmin, either in response to vascular injury or by therapeutic administration of thrombolytic agents, can also be expected to remove these RGDS sites,5z yet leave a highly thrombogenic surface intact. Here we have shown that localized fibrinolysis results in decreased platelet deposition, but this effect was not strongly correlated with plasmin degradation of the fibrin a chains. These observations may help to explain why rapid reocclusion after apparently successful thrombolytic therapy remains a major clinical problem.s6
